208 related articles for article (PubMed ID: 36062307)
21. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
22. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
23. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
[TBL] [Abstract][Full Text] [Related]
24. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells.
Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S
Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711
[TBL] [Abstract][Full Text] [Related]
25. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.
Lu Z; Yang H; Shao Y; Sun W; Jiang Y; Li J
Biochem Biophys Res Commun; 2022 Oct; 627():103-110. PubMed ID: 36030651
[TBL] [Abstract][Full Text] [Related]
26. Time Course of Changes in Sorafenib-Treated Hepatocellular Carcinoma Cells Suggests Involvement of Phospho-Regulated Signaling in Ferroptosis Induction.
Werth EG; Rajbhandari P; Stockwell BR; Brown LM
Proteomics; 2020 May; 20(10):e2000006. PubMed ID: 32336023
[TBL] [Abstract][Full Text] [Related]
27. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma.
Li Z; Liao X; Hu Y; Li M; Tang M; Zhang S; Mo S; Li X; Chen S; Qian W; Feng R; Yu R; Xu Y; Yuan S; Xie C; Li J
Free Radic Biol Med; 2023 May; 201():41-54. PubMed ID: 36924851
[TBL] [Abstract][Full Text] [Related]
28. Identification of ferroptosis-related genes for overall survival prediction in hepatocellular carcinoma.
Luo L; Yao X; Xiang J; Huang F; Luo H
Sci Rep; 2022 Jun; 12(1):10007. PubMed ID: 35705729
[TBL] [Abstract][Full Text] [Related]
29. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
Sun X; Ou Z; Chen R; Niu X; Chen D; Kang R; Tang D
Hepatology; 2016 Jan; 63(1):173-84. PubMed ID: 26403645
[TBL] [Abstract][Full Text] [Related]
30. Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma.
Yang X; Mei M; Yang J; Guo J; Du F; Liu S
Aging (Albany NY); 2022 May; 14(9):4069-4084. PubMed ID: 35550563
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of MCF2L Promoted the Ferroptosis of Hepatocellular Carcinoma Cells through PI3K/mTOR Pathway in a RhoA/Rac1 Dependent Manner.
Huang SC; Chen YM; Hu YY; Shi YJ; Xiao QW; Li Z; Kang JL; Zhou Q; Shen G; Jia HY
Dis Markers; 2022; 2022():6138941. PubMed ID: 36330204
[TBL] [Abstract][Full Text] [Related]
32. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma.
Huang CY; Chen LJ; Chen G; Chao TI; Wang CY
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232407
[TBL] [Abstract][Full Text] [Related]
33. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
[TBL] [Abstract][Full Text] [Related]
34. Integrative Multi-Omics Analysis of Identified Ferroptosis-Marker RPL8 as a Candidate Oncogene Correlates with Poor Prognosis and Immune Infiltration in Liver Cancer.
Fan S; Zhang S; Kong D; Wang H; Shi Y; Wang Z; Zheng H
Comb Chem High Throughput Screen; 2023; 26(7):1298-1310. PubMed ID: 36017842
[TBL] [Abstract][Full Text] [Related]
35. Molecular characteristics associated with ferroptosis in hepatocellular carcinoma progression.
Fei Z; Lijuan Y; Jing Z; Xi Y; Yuefen P; Shuwen H
Hum Cell; 2021 Jan; 34(1):177-186. PubMed ID: 32936424
[TBL] [Abstract][Full Text] [Related]
36. HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility.
Cui X; Yun X; Sun M; Li R; Lyu X; Lao Y; Qin X; Yu W
Hepatol Int; 2023 Apr; 17(2):377-392. PubMed ID: 36508088
[TBL] [Abstract][Full Text] [Related]
37. Ferroptosis-Related Hub Genes in Hepatocellular Carcinoma: Prognostic Signature, Immune-Related, and Drug Resistance Analysis.
Wang W; Pan F; Lin X; Yuan J; Tao C; Wang R
Front Genet; 2022; 13():907331. PubMed ID: 35938001
[No Abstract] [Full Text] [Related]
38. Development and validation of an immune-related prognosis signature associated with hypoxia and ferroptosis in hepatocellular carcinoma.
Yang CB; Feng HX; Dai CL
Cancer Med; 2022 Jun; 11(11):2329-2341. PubMed ID: 35092175
[TBL] [Abstract][Full Text] [Related]
39. Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy.
Li Q; Chen K; Zhang T; Jiang D; Chen L; Jiang J; Zhang C; Li S
Eur J Pharmacol; 2023 Sep; 955():175913. PubMed ID: 37460053
[TBL] [Abstract][Full Text] [Related]
40. Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.
Su Y; Zhang Z; Lee LTO; Peng L; Lu L; He X; Zhang X
Adv Healthc Mater; 2023 Jan; 12(6):e2202663. PubMed ID: 36653312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
